FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average bur	den					
hours per response	0.5					

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Print or Tv	pe Response	s)															
1. Name and Address of Reporting Person* Vincent Mark D.					2. Issuer Name and Ticker or Trading Symbol Aptose Biosciences Inc. [APTO]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105					3. Date of Earliest Transaction (Month/Day/Year) 01/31/2020								Officer (give	title below)		er (specify below)	
(Street) TORONTO, A6 M2J 4R3					4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) X. Form filed by One Reporting Person Form filed by More than One Reporting Person					
(Cit		(State)	(2	Zip)		Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea			2A. Deemed Execution Date, i any (Month/Day/Year		Date, if	(Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or (Amount (D) Price		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			Ý	6. 7. Nature Ownership Form: Beneficial Direct (D) or Indirect (I) (Instr. 4)			
Reminder:	Report on a s	separate line for eacl	1 class o		- Deriva	ıtive	Securiti	ies Acq	Person in this a current	ns who respondently valid Opposed of, or Beonvertible sec	t require MB cont eneficially	d to r rol nu	respond u umber.				74 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title of Und Securi	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficia Ownersh (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title		Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Director Option Grant	\$ 6.91 (1)	01/31/2020			A		154,00	00	(2)	01/30/203	Com Sha		154,000	\$ 0	154,000) D	
Repor	ting O	wners															
Director				Relationships				-									
				10% Owner		Officer	Other										
Vincent 1	Mark D.																

251 CONSUMERS ROAD, SUITE 1105 TORONTO, A6 M2J 4R3

Signatures

/s/ Gregory K. Chow, as attorney-in-fact for Mark D. Vincent	02/03/2020
**Signature of Reporting Person	Date

X

Explanation of Responses:

C/O APTOSE BIOSCIENCES INC.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Converted from Canadian exercise price of C\$9.10 using an exchange rate of 1.3169.
- (2) Fifty percent (50%) of the options vest on 1/31/2021. The remaining 50% vest as follows: one-half on 1/31/2022 and one-half on 1/31/2023.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are no	ot required to respond unless the form displays a currently valid OMB number.